Most of our readers will be familiar with the idea that progression of prostate cancer over time is associated with the expression of androgen receptors (ARs) in prostate cancer tissue. … READ MORE …
Filed under: Drugs in development | Tagged: androgen, pathway, receptor, ROR-γ | 2 Comments »
A key question in management of prostate cancer is the risk that a particular patient has disease — at the time of diagnosis — that will progress over time to become metastatic. The ability to answer this question with accuracy is fundamental to the need for aggressive, early treatment. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: damage, DNA, pathway, profile, prognosis, repair | 4 Comments »
Earlier this month The “New” Prostate Cancer InfoLink stated that the new liquid biopsy test being touted by Pathways Genomics was of no proven value in the diagnosis of prostate cancer and that we expected the U.S. Food and Drug Administration (FDA) would have some comments on the promotion of this test. We were correct. … READ MORE …
Filed under: Diagnosis | Tagged: biopsy, CancerIntercept, genomics, liquid, pathway | Leave a comment »
So today’s early morning session of the GU Oncology meeting was highly focused on the evolution of newer therapies affecting the androgen receptor pathways in the treatment of advanced and progressive forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, androgen, enzalutamide, new, pathway, therapies | Leave a comment »
